Skip to main content
. Author manuscript; available in PMC: 2020 Apr 15.
Published in final edited form as: J Neurol Sci. 2020 Jan 14;411:116687. doi: 10.1016/j.jns.2020.116687

Figure 1. Selection of OIPN cases and controls.

Figure 1.

OIPN case- and control groups of equal sizes were selected by extreme phenotype sampling.

A) A CONSORT diagram shows the selection of patients without OIPN (controls) and with OIPN (cases) identified by the rate of progression of OIPN symptoms with increasing cumulative oxaliplatin dose. Equal number of cases and controls were selected from the tail ends of the distribution of OIPN rates. Specifically, the OIPN rates were ordered by the upper bound of their rate confidence interval and the bottom 25% were taken as controls. Similarly, the cases were obtained by ordering the OIPN slopes by the lower bound of their CI and taking the top 25%. The red, blue, and grey colored points in the panel correspond to cases, controls and unselected patients.

B) Two examples showing extreme CIPN20 phenotypes. The left graph shows the data from the sensory subscale of the CIPN20 questionnaire for a patient who did not develop OIPN throughout his/her 12 cycles of chemotherapy. The right graph shows the example of a patient who quickly developed the symptoms of OIPN and had to be taken off the drug after 6 cycles.